Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity

Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity

Radiotherapy (RT) has been used to control tumors by physically damaging DNA and inducing apoptosis; it also promotes antitumor immune responses via neoantigens release and augmenting immune-oncology agents to elicit systemic response. Tumor regression after RT can recruit inflammatory cells, such a...

Full description

Bibliographic Details
Main Authors: Ahmed I. Younes, Hampartsoum B. Barsoumian, Duygu Sezen, Vivek Verma, Roshal Patel, Mark Wasley, Yun Hu, Joe D. Dunn, Kewen He, Dawei Chen, Hari Menon, Fatemeh Masrorpour, Meidi Gu, Liangpeng Yang, Nahum Puebla-Osorio, Maria Angelica Cortez, James W. Welsh
Format: Article
Language:English
Published: Elsevier 2021-02-01
Series:Translational Oncology
Subjects:
Cancer
Radiotherapy
Abscopal effect
TLR9 agonist
CMP-001
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523320304757

Internet

http://www.sciencedirect.com/science/article/pii/S1936523320304757

Similar Items